NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy

Area of Science:

• Oncology
• Molecular Biology
• Cellular Biology

Background:

• Combretastatin A-4 (CA-4) is a tubulin-depolymerizing agent with antitumor potential.
• Autophagy is a survival mechanism in cancer therapy; inhibiting it may improve treatment efficacy.
• N-myc downstream-regulated gene 1 (NDRG1) is crucial for cell survival and chemoresistance.

Purpose of the Study:

• To investigate the synergistic cytotoxic effect of CA-4 and autophagy inhibitor chloroquine (CQ) on human osteosarcoma (OS) cells.
• To elucidate the underlying mechanisms of CA-4 and CQ in regulating NDRG1 expression and function.
• To explore the role of NDRG1 in autophagy-lysosome fusion and its impact on cancer cell apoptosis.

Main Methods:

• Cell viability assays to assess synergistic cytotoxic effects.
• Luciferase reporter assays to determine transcriptional regulation of NDRG1.
• Immunofluorescence to analyze NDRG1 and lysosome colocalization.
• Western blotting to evaluate protein expression levels.
• siRNA-mediated knockdown of NDRG1 to assess its functional role.

Main Results:

• CA-4 induced cell-protective autophagy, and the combination of CA-4 and CQ exhibited synergistic cytotoxicity in OS cells.
• Both CA-4 and CQ independently increased NDRG1 expression.
• CA-4 transcriptionally upregulated NDRG1, while CQ prevented NDRG1 degradation by inhibiting lysosomal fusion.
• NDRG1 knockdown impaired lysosomal function, leading to autophagosome accumulation and increased apoptosis upon combination treatment.

Conclusions:

• The combination of CA-4 and CQ demonstrates synergistic efficacy against osteosarcoma by modulating autophagy and NDRG1.
• NDRG1 plays a critical role in autophagosome-lysosome fusion, and its abrogation sensitizes OS cells to CA-4 treatment.
• Targeting NDRG1 and autophagy concurrently presents a promising strategy for enhancing cancer therapy.